Package Insert: Information for the Patient
Vipdomet 12.5 mg/850 mg Film-Coated Tablets
Vipdomet 12.5 mg/1000 mg Film-Coated Tablets
alogliptin/hydrochloride of metformin
Read this package insert carefully before starting to take this medicine, as it contains important information for you.
What is Vipdomet
Vipdomet contains two different medications, called alogliptina and metformin, in a single tablet:
Both groups of medications are "oral antidiabetic medications".
What is Vipdomet used for
Vipdomet is used to decrease blood sugar levels in adults with type 2 diabetes. Type 2 diabetes is also known as non-insulin-dependent diabetes mellitus, or DMNID.
Vipdomet is taken when it is not possible to control blood sugar levels through diet, exercise, and other oral antidiabetic medications such as metformin alone, insulin alone, or metformin and pioglitazona taken together.
If you are already taking alogliptina and metformin in individual tablets, Vipdomet can replace them in a single tablet.
It is important that you do not stop following the diet and exercise advice that your doctor or nurse has given you.
Do not take Vipdomet
Warnings and precautions
Consult your doctor or pharmacist before taking Vipdomet:
Contact your doctor if you develop blisters on your skin, as this could be one of the signs of a condition called pemphigoid bullous. Your doctor will ask you to stop taking alogliptin.
Risk of lactic acidosis
Vipdomet may cause a rare but serious side effect called lactic acidosis, especially if your kidneys do not function properly. The risk of developing lactic acidosis is also increased with uncontrolled diabetes, severe infections, prolonged fasting or alcohol consumption, dehydration (see below for more information), liver problems, and any medical condition in which a part of the body has a reduced oxygen supply (such as acute and severe heart disease).
If any of the above applies to you, consult your doctor for further instructions.
Stop taking Vipdomet for a short period if you have a condition that may be associated with dehydration(significant loss of body fluids), such as intense vomiting, diarrhea, fever, exposure to heat, or if you drink less liquid than normal. Consult your doctor for further instructions.
Stop taking Vipdomet and contact a doctor or the nearest hospital immediately if you experience any of the symptoms that produce lactic acidosis, as this condition can lead to coma.
Lactic acidosis is a medical emergency and should be treated in a hospital. If you suspect you have lactic acidosis, visit your doctor or hospital for medical attention.
The symptoms of lactic acidosis include:
If you need to undergo major surgery, stop taking Vipdomet while the procedure is being performed and for a time after it. Your doctor will decide when to interrupt Vipdomet treatment and when to restart it.
During Vipdomet treatment, your doctor will check your kidney function at least once a year or more frequently if you are an elderly person and/or if your kidney function is worsening.
Children and adolescents
Vipdomet is not recommended for children and adolescents under 18 years of age, due to the lack of data in these patients.
Other medications and Vipdomet
If you need to receive an intravenous injection of a contrast medium containing iodine, for example, in the context of a radiograph or examination, stop taking Vipdomet before the injection or at the time of the injection. Your doctor will decide when to interrupt Vipdomet treatment and when to restart it.
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication. You may need more frequent blood glucose and kidney function tests, or your doctor may need to adjust your Vipdomet dose. It is especially important to mention the following:
Vipdomet and alcohol
Avoid excessive alcohol consumption while taking Vipdomet, as this may increase the risk of lactic acidosis (see "Warnings and precautions" section).
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or if you think you may be pregnant or plan to become pregnant, consult your doctor or pharmacist before using this medication. Do not take Vipdomet if you are pregnant.
Vipdomet is not recommended during breastfeeding, as metformin passes into breast milk.
Driving and operating machinery
It is not known if Vipdomet affects the ability to drive and operate machinery. Taking Vipdomet in combination with medications called pioglitazone or insulin may cause excessively low blood sugar (hypoglycemia), which could affect your ability to drive and operate machinery
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
Your doctor will tell you exactly how much Vipdomet you need to take. The amount of Vipdomet will vary according to your condition and the doses of metformin alone, metformin in combination with pioglitazona, insulin, and/or individual tablets of alogliptina and metformina you are currently taking.
The recommended dose is one tablet twice a day. If you have reduced renal function, your doctor may prescribe a lower dose that may need to be supplied in separate tablets of alogliptina and metformina.
Swallow the tablets whole with water. You should take this medication with food to reduce the possibility of stomach discomfort.
If you take more Vipdomet than you should
If you take more tablets than you should, or if someone else or a child takes your medication, contact or go immediately to the nearest emergency center. Bring this leaflet or some tablets with you, so your doctor knows exactly what you have taken.
If you forget to take Vipdomet
If you forget to take a dose, take it as soon as you remember. Do not take a double dose to make up for a missed dose.
If you interrupt treatment with Vipdomet
Do not stop taking Vipdomet without first consulting your doctor. Your blood glucose levels may increase if you stop taking Vipdomet.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine may cause side effects, although not everyone will experience them.
STOP taking Vipdomet and immediately contact a doctor or the nearest hospitalif you notice any symptoms of the followingserious side effects:
Very rare(may affect up to 1 in 10,000 people):
Of unknown frequency(cannot be estimated from available data):
You should alsoconsult your doctorif you experience any of the following side effects:
Very common(may affect more than 1 in 10 people):
Common(may affect up to 1 in 10 people):
Very rare:
Of unknown frequency:
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through thenational reporting system included in theAppendix V. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the box and on the blister pack after CAD/EXP. The expiration date is the last day of the month indicated.
No special storage conditions are required.
Medicines should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the containers and medications that you no longer need. By doing so, you will help protect the environment.
Composition of Vipdomet
Each film-coated tablet of 12.5 mg/850 mg contains benzoate of alogliptin equivalent to 12.5 mg of alogliptin and 850 mg of metformin hydrochloride.
Each film-coated tablet of 12.5 mg/1000 mg contains benzoate of alogliptin equivalent to 12.5 mg of alogliptin and 1000 mg of metformin hydrochloride.
Appearance of the product and contents of the pack
Vipdomet is available in blisters with 10, 14, 20, 28, 56, 60, 98, 112, 120, 180, 196, or 200 film-coated tablets and multiple packs with 2 packs each containing 98 film-coated tablets.
Only some pack sizes may be marketed.
Marketing Authorization Holder
Takeda Pharma A/S
Delta Park 45
2665 Vallensbaek Strand
Denmark
Responsible for manufacturing
Takeda Ireland Limited
Bray Business Park
Kilruddery
Co. Wicklow
Ireland
For more information about this medicinal product, please contact the local representative of the marketing authorization holder:
België/Belgique/Belgien Takeda Belgium NV Tel/Tél: +32 2 464 06 11 | Lietuva Takeda, UAB Tel: +370 521 09 070 |
Luxembourg/Luxemburg Takeda Belgium NV Tel/Tél: +32 2 464 06 11 | |
Ceská republika Takeda Pharmaceuticals Czech Republic s.r.o. Tel: +420 234 722 722 | Magyarország Takeda Pharma Kft. Tel: +36 1 270 7030 |
Danmark Takeda Pharma A/S Tlf: +45 46 77 10 10 | Malta Takeda HELLAS S.A. Tel: +30 210 6387800 |
Deutschland Takeda GmbH Tel: +49 (0)800 825 3325 | Nederland Takeda Nederland B.V. Tel: +31 20 203 5492 |
Eesti Takeda Pharma AS Tel: +372 6177 669 | Norge Takeda AS Tlf: +47 800 800 30 |
Ελλáδα Takeda ΕΛΛΑΣ Α.Ε. Τηλ: +30 210 6387800 | Österreich Takeda Pharma Ges. m.b.H. Tel: +43 (0) 800-20 80 50 |
España Laboratorios Menarini, S.A Tel: +34 934 628 800 | Polska Takeda Pharma Sp.z o.o. tel: +48223062447 |
France Takeda France SAS Tel: + 33 1 40 67 33 00 | Portugal Tecnimede - Sociedade Técnico-Medicinal, S.A Tel: +351 21 041 41 00 |
Hrvatska Takeda Pharmaceuticals Croatia d.o.o Tel: +385 1 377 88 96 | România Takeda Pharmaceuticals SRL Tel: +40 21 335 03 91 |
Ireland Takeda Products Ireland Ltd Tel: 1800 937 970 | Slovenija Takeda Pharmaceuticalsfarmacevtska družba d.o.o. Tel: +386 (0) 59 082 480 |
Ísland Vistor hf. Sími: +354 535 7000 | Slovenská republika Takeda Pharmaceuticals Slovakia s.r.o. Tel: +421 (2) 20 602 600 |
Italia Takeda Italia S.p.A. Tel: +39 06 502601 | Suomi/Finland Takeda Oy Puh/Tel: 0800 774 051 |
Κúpρος Takeda ΕΛΛΑΣ Α.Ε. Τηλ: +30 210 6387800 | Sverige Takeda Pharma AB Tel: 020 795 079 medinfo[email protected] |
Latvija Takeda Latvia SIA Tel: +371 67840082 | United Kingdom (Northern Ireland) Takeda UK Ltd Tel: +44 (0) 2830 640 902 |
Last update of the summary of product characteristics:
Other sources of information
The detailed information on this medicinal product is available on the website of the European Medicines Agency:http://www.ema.europa.eu.
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.